These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 28673254)

  • 41. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
    Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
    Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
    Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia.
    Boettiger DC; Khol V; Durier N; Law M; Sun LP
    Antivir Ther; 2016; 21(8):725-730. PubMed ID: 27124891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
    Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
    J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
    Galli L; Spagnuolo V; Bigoloni A; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Borderi M; Gibellini D; Caramatti G; Lazzarin A; Castagna A;
    J Antimicrob Chemother; 2016 Jun; 71(6):1637-42. PubMed ID: 26945711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study.
    Kan W; Teng T; Liang S; Ma Y; Tang H; Zuohela T; Sun G; He C; Wall KM; Marconi VC; Liao L; Leng X; Liu P; Ruan Y; Xing H; Shao Y
    BMJ Open; 2017 Sep; 7(9):e016012. PubMed ID: 28882911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
    Lambert-Niclot S; Masquelier B; Cohen Codar I; Soulie C; Delaugerre C; Morand-Joubert L; Charpentier C; Ferre V; Plantier JC; Montes B; Carret S; Perrot V; Peytavin G; Costagliola D; Calvez V; Marcelin AG;
    J Antimicrob Chemother; 2012 Oct; 67(10):2487-93. PubMed ID: 22733652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
    Geretti AM; Abdullahi A; Mafotsing Fopoussi O; Bonnett L; Fokom Defo V; Moudourou S; Fokam J; Kouanfack C; Torimiro J
    J Antimicrob Chemother; 2019 Oct; 74(10):3011-3015. PubMed ID: 31299067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
    Belmonti S; Lombardi F; Quiros-Roldan E; Latini A; Castagna A; Borghetti A; Baldin G; Ciccullo A; Cauda R; De Luca A; Di Giambenedetto S;
    J Antimicrob Chemother; 2018 Jul; 73(7):1949-1954. PubMed ID: 29788156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia.
    Nega J; Taye S; Million Y; Rodrigo C; Eshetie S
    AIDS Res Ther; 2020 Jul; 17(1):39. PubMed ID: 32650796
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
    Afrane AKA; Goka BQ; Renner L; Yawson AE; Alhassan Y; Owiafe SN; Agyeman S; Sagoe KWC; Kwara A
    BMC Infect Dis; 2021 Aug; 21(1):731. PubMed ID: 34340689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
    Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
    HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV-infected patients on first-line antiretroviral therapy from Tanzania.
    Kroidl A; Burger T; Urio A; Mugeniwalwo R; Mgaya J; Mlagalila F; Hoelscher M; Däumer M; Salehe O; Sangare A; Lennemann T; Maganga L
    Trop Med Int Health; 2020 May; 25(5):579-589. PubMed ID: 31984634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
    Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
    HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome of patients on second line antiretroviral therapy under programmatic condition in India.
    Chakravarty J; Sundar S; Chourasia A; Singh PN; Kurle S; Tripathy SP; Chaturbhuj DN; Rai M; Agarwal AK; Mishra RN; Paranjape RS
    BMC Infect Dis; 2015 Nov; 15():517. PubMed ID: 26572102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
    Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
    Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.